The role of polymorphisms in ADAM33, a disintegrin and metalloprotease 33, in childhood asthma and lung function in two German populations

1465-9921-7-91 RRJ Research The role of polymorphisms in ADAM33, a disintegrin and metalloprotease 33, in childhood asthma and lung function in two German populations Schedel Michaela michaela.schedel@med.uni-muenchen.de Depner Martin martin.depner@med.uni-muenchen.de Schoen Carola carola.schoen@med.uni-muenchen.de Weiland K Stephan stephan.weiland@uni-ulm.de Vogelberg Christian Christian.Vogelberg@uniklinikum-dresden.de Niggemann Bodo bodo.niggemann@charite.de Lau Susanne susanne.lau@charite.de Illig Thomas illig@gsf.de Klopp Norman klopp@gsf.de Wahn Ulrich ulrich.wahn@charite.de von Mutius Erika erika.von.mutius@med.uni-muenchen.de Nickel Renate renate.nickel@charite.de Kabesch Michael michael.kabesch@med.uni-muenchen.de

University Children's Hospital, Ludwig Maximilian's University Munich, Germany

Department of Epidemiology, University of Ulm, Germany

University Children's Hospital Dresden, Germany

Department of Pediatric Pneumology and Immunology, Charité Humbolt University Berlin, Germany

Institute of Epidemiology, GSF -Research Centre for Environment and Health, Neuherberg, Germany

Respiratory Research 1465-9921 2006 7 1 91 http://respiratory-research.com/content/7/1/91 16784537 10.1186/1465-9921-7-91 28 3 2006 19 6 2006 19 6 2006 2006 Schedel et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

ADAM33, the first asthma candidate gene identified by positional cloning, may be associated with childhood asthma, lung function decline and bronchial hyperresponsiveness. However, replication results have been inconclusive in smaller previous study populations probably due to inconsistencies in asthma phenotypes or yet unknown environmental influences. Thus, we tried to further elucidate the role of ADAM33 polymorphisms (SNPs) in a genetic analysis of German case control and longitudinal populations.

Methods

Using MALDI-TOF, ten ADAM33 SNPs were genotyped in 1,872 children from the International Study of Asthma and Allergy in Childhood (ISAAC II) in a case control setting and further 824 children from the longitudinal cohort Multicentre Study of Allergy (MAS). In both populations the effects of single SNPs and haplotypes were studied and a gene environment analysis with passive smoke exposure was performed using SAS/Genetics.

Results

No single SNP showed a significant association with doctor's diagnosis of asthma. A trend for somewhat more profound effects of ADAM33 SNPs was observed in individuals with asthma and BHR. Haplotype analyses suggested a minor effect of the ADAM33 haplotype H4 on asthma (p = 0.033) but not on BHR. Associations with non atopic asthma and baseline lung function were identified but no interaction with passive smoke exposure could be detected.

Conclusion

The originally reported association between ADAM33 polymorphisms and asthma and BHR could not be confirmed. However, our data may suggest a complex role of ADAM33 polymorphisms in asthma ethiology, especially in non atopic asthma.

Background

ADAM33, a disintegrin and metalloproteinase 33 has been the first gene published, which had been identified by positional cloning as a putative candidate gene for the development of asthma and bronchial hyperresponsiveness 1. It has been speculated that the ADAM33 gene, expressed in airway smooth muscle cells and fibroblasts of the lung, codes for a protein important for cell fusion, cell adhesion, cell signalling and proteolysis. Furthermore, ADAM33 was suggested to play a role in airway remodeling 2.

The ADAM33 gene is located on chromosome 20p13 and 37 SNPs have initially been identified 1. Ever since the first report of association between ADAM33 polymorphisms and asthma in two Caucasian populations from the UK and the USA, a number of replication studies have been published with very diverse results. Various associations between different asthma phenotypes as well as with BHR and several different SNPs in the gene have been reported 34567. One possible explanation for this diversity in replication results could be the heterogeneity between study populations or between the definitions of asthma in different study populations. It can be hypothesized that ADAM33, involved in remodeling, may be especially important in some specific forms of asthma. Thus, it may be more relevant in adult or non-atopic than in atopic asthma. Furthermore, it may affect lung function more than atopy status. Finally, environmental factors such as passive smoke exposure could potentially interact with ADAM33 in exerting its remodeling function in the lung as ADAM33 also seems to be involved in COPD mediated processes8.

We tested the hypothesis that the ADAM33 gene is associated with atopic or non atopic asthma, lung function and BHR in a large nested case control study of German children (N = 1,872; comparing 624 asthmatics and/or BHR positives and 1,248 non-asthmatic, BHR negative, non-atopic controls) and a German multicentre family based birth cohort study (MAS) (888 children with DNA available, 96 asthmatics and 792 non-asthmatics). The effect of ten SNPs spanning the ADAM33 gene as indicated in figure 1, previously showing associations with asthma phenotypes in some populations, and haplotypes of these SNPs were analysed.

Figure 1

Position of the genotyped polymorphisms (SNPs) in the ADAM33 gene in respect to the 22 exons (blue) and untranslated regions (red) of the gene

Position of the genotyped polymorphisms (SNPs) in the ADAM33 gene in respect to the 22 exons (blue) and untranslated regions (red) of the gene. SNPs nomenclature according to the initial report by Van Eerdewegh et al. and alternatively according to the rs system in brackets.

Methods

Description of the case control study population

Between 1995 and 1996, cross sectional studies were conducted in Munich (ISAAC II), Dresden (ISAAC II) and Leipzig to assess the prevalence of asthma and allergies in schoolchildren age 9 to 11 years 910. As the populations and phenotyping methods have been described in detail before 9, only an overview of the methods pertaining to this analysis is given here. Parental questionnaires for self-completion were sent through the schools to the families including the ISAAC core questions while slightly different questionnaires were used for the Leipzig population 9. All children in the three cities whose parents reported that a doctor diagnosed "asthma" at least once or "asthmatic, spastic or obstructive bronchitis" more than once were defined as having asthma.

In Dresden and Munich, children underwent skin prick testing for six common aeroallergens (Dermatophagoides pteronyssinus, D. farinae, Alternaria tenuis, cat dander, and mixed grass and tree pollen) while in Leipzig D. pteronyssinus, grass, birch and hazel pollen, cat and dog dander was examined 10. A positive skin reaction was defined as a wheal size ≥ 3 mm after subtraction of the negative control 9.

In the Munich and Dresden population, standard baseline lung function was measured and bronchial reactivity was assessed in a random 50% sub-sample of the study population by inhalation of nebulized, hyperosmolar saline (4.5%). Children with a drop in FEV₁of 15% or more from baseline were classified as positive for bronchial hyperresponsiveness 9. In the Leipzig population, measurements of airway challenges utilizing cold-air challenge were performed according to a previously published protocol 10. In this case BHR was defined as a fall in FEV₁of 9% corresponding to a value as large or larger than the 95th percentile of the reference population 11.

For this analysis, all children of German origin who had both DNA and IgE data available and had a doctor's diagnosis of asthma and/or showed BHR (N = 624, Munich n = 230, Dresden n = 263, Leipzig n = 131) were selected from the total study population. These children were matched at a 1:2 ratio with a random selection of healthy, non asthmatic, non atopic children without a diagnosis of BHR (Munich n = 460, Dresden n = 526, Leipzig n = 262) in the analysis.

Multicentre Allergy Study cohort

The German Multicentre Allergy Study (MAS) cohort has been described in detail elsewhere 1213. Initially, 1,314 children born in five German cities in the year 1990 were followed up from birth to the age of 13 years. For 888 children DNA was available and of these, only children of German origin were included in this study (n = 824). Yearly follow-up visits included standardized interviews, questionnaires, and physical examinations. In the MAS study, asthma, hay fever and atopic dermatitis at age 10 were defined using the ISAAC-core questions for children as described for the ISAAC study population.

Serum samples were obtained from the children at birth, and at 1, 2, 3, 5, 6, 7 and 10 years of age. Total IgE, specific IgE antibodies to food allergens and inhalant allergens (Dermatophagoides pteronyssinus, cat dander, mixed grass, birch pollen, as well as dog dander from age 3 years on) were determined by CAP-RAST FEIA (Pharmacia & Upjohn, Freiburg, Germany). In the MAS study, atopy was defined as a specific IgE level (CAP I) of ≥ 0.35 kU/l at age 7 or 10 years, respectively.

While pulmonary function tests were performed at age 7, 10 and 13, bronchial hyperresponsiveness was only assessed at age 7 in 610 individuals 14. Bronchial challenges in the MAS study were conducted after baseline spirometry using increasing concentrations of histamine (usually from 0.5 mg/ml to 8.0 mg/ml) according to standard procedures. The 90^thpercentile of the distribution of PC₂₀FEV₁in a healthy subsample corresponded to 0.85 mg/ml. Bronchial hyperresponsiveness was defined as a PC₂₀FEV₁greater than this value.

Current environmental smoke exposure was defined as any current environmental tobacco smoke exposure at the age of the survey in ISAAC (9–11) and at the age 10-survey in MAS according to the information derived from parental questionnaires. In utero exposure to maternal smoking was assessed by a positive answer to the question "Did the mother of the child smoke during pregnancy?". Informed written consent was obtained from all parents of children included in the ISAAC and MAS studies. All study methods were approved by the local ethics committees.

Genotyping methods

For genotyping, the MassARRAY system (Sequenom, San Diego, USA) was used as previously described in detail 15. All PCR reactions were performed using standard thermocyclers (MJ Research, Waltham, USA). First, a PCR was carried out. To remove excessive dNTPs, shrimp alkaline phosphatase was added to the PCR products. The base-specific extension reaction was performed in 10 μl reactions by Thermosequenase (Amersham, Piscataway, USA). For the base extension reaction the denaturation was performed at 94°C for 2 min, followed by 94°C for 5 sec, 52°C for 5 sec, and 72°C for 10 sec for 55 cycles. The final base extension products were treated with SpectroCLEAN resin to remove salts out of the reaction buffer, and 16 μl of water was added into each base extension reaction. After a quick centrifugation (2,000 rpm, 3 min) the reaction solution was dispensed onto a 384 format SpectroCHIP pre-spotted with a matrix of 3-hydroxypicolinic acid (3-HPA) by using a SpectroPoint nanodispenser. A modified Bruker Biflex matrix assisted laser desorption ionization-time-of-flight mass spectrometer was used for data acquisitions from the SpectroCHIP. Genotyping calls were made in real time with MASSARRAY RT software (Sequenom, San Diego, USA).

Statistical analysis

Deviations from Hardy-Weinberg equilibrium were investigated for all polymorphisms using the χ²statistic, with expected frequencies derived from allele frequencies. Associations between SNPs and qualitative outcomes were determined using Cochran-Armitage-Trend-tests and χ²-tests in dominant models of the rare allele. Differences in lung function parameters were tested by univariate variance analysis and t-tests in dominant or recessive models.

Linkage Disequilibrium (LD) and the LD block structure were assessed using Haploview 16 and haplotype analysis was performed for all tagging SNPs after haplotype frequencies had been estimated by the EM (expectation-maximisation) algorithm 17. Haplotype associations with asthma and BHR were calculated with the haplotype procedure in SAS/Genetics. In addition, haplotype trend regression models were estimated, where the estimated probabilities of the haplotypes were modelled in a logistic regression as independent variables 18.

For asthma as a binary outcome, logistic regression models for gene-environment interactions were used to estimate the combined effect of each SNP with exposure to environmental tobacco smoke (in utero and at time of survey). A Botto Khoury approach summarizing the data in a 2 × 4 table allowed for the evaluation of the independent and combined roles of genotype and exposure on disease risk 19.

All statistical analyses were carried out using the SAS statistical software package (Version 9.1) and the SAS/Genetics module.

Results

Ten polymorphisms previously identified and showing associations in at least one replication study were selected for genotyping (table 1). These SNPs, located in the 3' half of the gene, spanned the known ADAM33 linkage structure as indicated in figure 1. Call rates for SNPs in ADAM33 ranged from 90.9% to 93.7% in the family based study population, from 92.1% to 94.3% in the case control population and from 91.9% to 94.0% in the pooled sample as indicated in table 1. All SNPs were in Hardy Weinberg equilibrium in both populations. In the population based cross sectional study populations from East and West Germany, all SNPs showed allele frequencies similar to those previously published in other Caucasian populations (table 1). Genotype frequencies and linkage disequilibrium were almost identical in both the case control population and the MAS cohort (data not shown).

Table 1

Description of the investigated ADAM33 SNPs and assay conditions in the case control and cohort study population.

position in original publication

rs numbers

Alleles

Minor Allele Frequency

PCR Primer

Extension Primer

Callrate (%)

Case Control

Cohort based

F+1

rs511898

G/A

0.38

0.36

fwd ACGTTGGATGAAAATACTGGGACTCGAGGC

rev ACGTTGGATGTGCTGTATCTATAGCCCTCC

ACTCGAGGCCTGTGAATTCC

93.73

M+1

rs3918395

G/T

0.15

0.13

fwd ACGTTGGATGGGGCACCAATTAACTAAGGC

rev ACGTTGGATGTGAGGGCATGGAAGGTTCAG

GCCGGCTCCCAAGCTCC

92.03

rs3918396

G/A

0.09

fwd ACGTTGGATGAGTCGGTAGCAACACCAGGC

rev ACGTTGGATGAATCCCCGCAGACCATGACAC

CCTGCTGGCCATGCTCCTCAGC

92.99

rs528557

G/C

0.28

fwd ACGTTGGATGAGTCGGTAGCAACACCAGG

rev ACGTTGGATGACCATGACACCTTCCTGCTG

GCTGCCTCTGCTCCCAGG

91.88

ST+4

rs44707

A/C

0.41

fwd ACGTTGGATGGGAGTGAAAAGATGTGCTGG

rev ACGTTGGATGCCACTTCCTCTGCACAAATC

ACAAATCACCTCTGTCACCC

92.58

ST+5

rs597980

C/T

0.44

0.45

fwd ACGTTGGATGAGAGAACTGGGTTAAGGCAG

rev ACGTTGGATGCCAGCACATCTTTTCACTCC

ACTCCATACCACTGGTCAGCTG

93.81

ST+7

rs574174

G/A

0.19

fwd ACGTTGGATGCTGCCCTTGATGATTCCAAG

rev ACGTTGGATGGGAACATCACAGGAAATGAC

ACTGTCCCCATCCCATC

93.66

rs2280091

T/C

0.16

0.14

fwd ACGTTGGATGTTCCCTTCTCCCTTCCCTCTC

rev ACGTTGGATGTTGCTCAGCCCCAAAGATGG

GGGCGGCGTTCACCCCA

93.77

rs2280090

C/T

0.16

0.14

fwd ACGTTGGATGTTCCCTTCTCCCTTCCCTCTC

rev ACGTTGGATGTTGCTCAGCCCCAAAGATGG

CCCCACAGCCACTGGACAG

93.95

rs2787094

C/G

0.22

0.23

fwd ACGTTGGATGAGAAACAGGAAGGAAGGTCC

rev ACGTTGGATGTATGGTTCGACTGAGTCCAC

CTGAGTCCACACTCCCCTG

93.84

Single SNP analyses with qualitative traits

Associations between ADAM33 polymorphisms and the phenotypes asthma and BHR were investigated in both populations. As children in the case control sample were 9–11 years old at the time of disease status assessment and children in the longitudinal MAS study population were assessed using the same ISAAC core questions at age 10, all analyses of association with asthma in the MAS population were also performed at this and no other age. As BHR values were only available at age 7 but not at age 10 in the MAS population, BHR was analyzed separately in both populations.

No significant association could be detected between any tested SNP and doctor's diagnosed asthma, neither in the case control population nor in the cohort study, nor in the pooled dataset (table 2). However, the risk to develop non atopic asthma (as defined as a doctor's diagnosis of asthma in the absence of a positive skin prick test) was increased in carriers of the polymorphic A allele in S1 (OR 1.53, 95%CI 1.01–2.31, p = 0.042) and in carriers of the polymorphic G allele in V4 (OR 1.44, 95%CI 1.03–2.01, p = 0.031). Furthermore, the risk for non atopic asthma was decreased in carriers of the polymorphic T allele for M+1 (OR = 0.60, 95%C.I. 0.40 – 0.91, p = 0.016).

Table 2

Odds ratios (OR) and 95% confidence intervals (95% CI) for the association between single ADAM33 polymorphisms and asthma and BHR in the case-control population (age 9–11) and in the cohort study population assessed at age ten for asthma and age seven for BHR.

Asthma

BHR¹

Asthma and BHR²

SNP

case-control study

cohort study

pooled

case-control study

cohort study

case-control study

F+1

0.92 (0.72–1.17)

p = 0.502

0.94 (0.58–1.52)

p = 0.795

0.92 (0.74–1.15)

p = 0.478

1.27 (0.96–1.69)

p = 0.095

1.01 (0.63–1.61)

p = 0.962

1.61 (0.90–2.88)

p = 0.105

M+1

0.86 (0.65–1.13)

p = 0.269

0.94 (0.53–1.65)

p = 0.819

0.89 (0.70–1.14)

p = 0.351

1.18 (0.88–1.59)

p = 0.274

1.03 (0.61–1.74)

p = 0.919

1.46 (0.84–2.54)

p = 0.177

1.23 (0.90–1.69)

p = 0.201

1.16 (0.64–2.10)

p = 0.635

1.20 (0.90–1.58)

p = 0.210

1.27 (0.90–1.81)

p = 0.175

1.19 (0.67–2.14)

p = 0.552

1.10 (0.54–2.25)

p = 0.789

0.99 (0.78–1.26)

p = 0.949

0.97 (0.60–1.56)

p = 0.893

0.99 (0.80–1.22)

p = 0.908

1.29 (0.98–1.69)

p = 0.073

1.00 (0.63–1.59)

p = 0.989

1.72 (0.99–3.00)

p = 0.052

ST+4

1.04 (0.81–1.34)

p = 0.766

1.31 (0.79–2.18)

p = 0.292

1.10 (0.87–1.37)

p = 0.432

0.99 (0.74–1.32)

p = 0.956

1.08 (0.67–1.74)

p = 0.762

1.22 (0.69–2.18)

p = 0.490

ST+5

0.94 (0.73–1.22)

p = 0.649

0.80 (0.48–1.33)

p = 0.384

0.89 (0.71–1.12)

p = 0.338

0.95 (0.71–1.28)

p = 0.748

1.20 (0.71–2.00)

p = 0.495

0.91 (0.51–1.60)

p = 0.731

ST+7

1.11 (0.86–1.42)

p = 0.428

1.16 (0.71–1.89)

p = 0.549

1.10 (0.88–1.38)

p = 0.384

1.20 (0.90–1.59)

p = 0.209

1.15 (0.72–1.84)

p = 0.562

0.96 (0.55–1.70)

p = 0.901

0.96 (0.74–1.25)

p = 0.762

0.92 (0.53–1.60)

p = 0.764

0.97 (0.76–1.23)

p = 0.804

1.20 (0.90–1.61)

p = 0.213

1.12 (0.67–1.88)

p = 0.662

1.50 (0.87–2.59)

p = 0.141

0.95 (0.73–1.24)

p = 0.711

0.88 (0.50–1.55)

p = 0.666

0.96 (0.76–1.22)

p = 0.731

1.21 (0.91–1.62)

p = 0.196

1.14 (0.68–1.91)

p = 0.622

1.51 (0.88–2.61)

p = 0.134

1.22 (0.95–1.55)

p = 0.115

0.82 (0.51–1.34)

p = 0.439

1.11 (0.90–1.38)

p = 0.329

1.13 (0.85–1.49)

p = 0.402

1.13 (0.71–1.78)

p = 0.608

1.31 (0.76–2.26)

p = 0.332

¹No pooled analysis because of different techniques of BHR assessment in the case-control study and in the cohort study

²No analysis in the cohort study because of low number of cases

No significant association between ADAM33 polymorphisms and BHR, assessed by histamine challenge in the MAS population at age 7 or with hypertonine saline inhalation or cold air challenge in the case control population at age 9–11, was observed as shown in table 2. As the initial study by van Eerdewegh et al. 1 suggested the major effect of ADAM33 polymorphisms in individuals with asthma and concomitant BHR, we investigated this specific phenotype in the case control population. Again, no SNP reached statistical significance in the association analysis (table 2). As BHR values were only available at age 7 but not at age 10 in the MAS cohort study and different procedures were used to define BHR in both study populations, no combined analysis with both outcome variables was performed.

Single SNP analyses with lung function measurements

Next, the effects of ADAM33 SNPs on baseline lung function measurements (FVC, FEV1, MEF25, MEF50 and MEF75) were investigated in cases (asthma and/or BHR positive) and controls separately (table 3). In cases, FVC was increased in carriers of S2, T1 and T2 polymorphisms while FEV1 was increased in carriers of S2 and M+1 polymorphisms. In contrast to polymorphism S1, the presence of the polymorphic C allele in S2 increased the values for MEF75. In controls, negative effects on MEF50 were observed with ST+5 and MEF75 was increased in carriers of the M+1 or S2 SNP.

Table 3a

Lung function parameters in the case-control study for all cases *)

SNP

N ¹⁾

MEF₂₅(%) Mean ± SD

MEF₅₀(%) Mean ± SD

MEF₇₅(%) Mean ± SD

FEV1 (%) Mean ± SD

FVC (%) Mean ± SD

F+1

wild type

165

89.82 ± 29.66

89.47 ± 22.54

91.90 ± 16.28

97.65 ± 11.44

97.64 ± 11.03

heterozygous

232

91.86 ± 32.06

91.22 ± 22.23

94.48 ± 18.53

99.32 ± 10.57

99.80 ± 10.02

homozygous

92.61 ± 23.45

90.28 ± 17.19

97.32 ± 18.00

98.56 ± 10.75

98.16 ± 10.75

M+1

wild type

317

90.75 ± 30.97

89.70 ± 22.29

93.19 ± 17.82

98.17 ± 11.43*^r

98.12 ± 11.05

heterozygous

128

91.28 ± 28.43

91.51 ± 22.15

95.56 ± 17.50

99.01 ± 9.86

99.86 ± 9.83

homozygous

109.34 ± 23.03

98.95 ± 12.38

95.75 ± 23.07

109.31 ± 9.13

105.89 ± 9.71

wild type

359

90.57 ± 30.08

90.00 ± 21.74

93.23 ± 17.00*^v

98.29 ± 10.86

98.46 ± 10.72

heterozygous

94.29 ± 31.08

92.01 ± 24.43

97.23 ± 21.03

99.63 ± 11.23

99.58 ± 10.02

homozygous

73.47 ± 16.07

76.17 ± 10.97

78.46 ± 11.72

90.84 ± 5.11

96.06 ± 1.40

wild type

215

91.22 ± 31.50

89.69 ± 22.15

92.14 ± 17.03*^d

97.50 ± 11.49*^d

96.97 ± 11.32*^v*^d

heterozygous

202

91.30 ± 29.78

91.43 ± 22.16

96.12 ± 18.27

99.76 ± 10.73

100.55 ± 9.99

homozygous

95.31 ± 21.52

90.93 ± 22.04

94.54 ± 20.57

99.55 ± 9.27

98.70 ± 9.25

ST+4

wild type

158

90.05 ± 29.28

89.70 ± 22.41

93.18 ± 18.52

98.08 ± 10.38

99.09 ± 10.01

heterozygous

223

92.00 ± 29.50

91.32 ± 22.23

94.83 ± 18.14

99.06 ± 11.75

98.61 ± 11.11

homozygous

92.97 ± 34.91

90.22 ± 22.04

93.93 ± 14.12

98.68 ± 10.03

98.59 ± 11.39

ST+5

wild type

136

92.47 ± 31.51

91.10 ± 20.52

94.37 ± 15.25

99.26 ± 10.00

99.38 ± 10.88

heterozygous

236

91.87 ± 29.26

91.02 ± 23.37

94.65 ± 19.04

98.79 ± 11.61

98.62 ± 10.58

homozygous

87.50 ± 29.64

87.41 ± 20.55

91.39 ± 17.77

97.13 ± 10.41

98.48 ± 10.15

ST+7

wild type

285

90.28 ± 29.48

90.36 ± 21.92

93.30 ± 16.83

98.67 ± 10.93

99.10 ± 10.49

heterozygous

158

94.26 ± 31.56

91.07 ± 22.55

94.99 ± 19.60

98.98 ± 11.11

98.63 ± 10.92

homozygous

82.30 ± 24.76

82.94 ± 17.26

95.38 ± 16.31

93.87 ± 9.08

95.04 ± 7.62

wild type

315

90.42 ± 31.04

89.55 ± 22.40

93.32 ± 17.78

98.07 ± 11.38

98.12 ± 10.83*^d

heterozygous

135

92.59 ± 28.08

92.22 ± 21.39

95.50 ± 17.87

99.42 ± 9.78

100.10 ± 9.98

homozygous

98.09 ± 27.48

90.95 ± 23.47

91.61 ± 19.64

103.91 ± 11.37

103.30 ± 8.53

wild type

317

90.60 ± 31.04

89.61 ± 22.34

93.37 ± 17.71

98.13 ± 11.36

98.14 ± 10.80*^d

heterozygous

135

92.59 ± 28.08

92.22 ± 21.39

95.50 ± 17.87

99.42 ± 9.78

100.10 ± 9.98

homozygous

98.09 ± 27.48

90.95 ± 23.47

91.61 ± 19.64

103.91 ± 11.37

103.30 ± 8.53

wild type

267

91.58 ± 30.15

89.98 ± 21.82

93.12 ± 17.14

98.24 ± 11.04

98.22 ± 10.82

heterozygous

163

89.70 ± 30.05

89.71 ± 22.19

94.63 ± 18.60

98.57 ± 10.65

99.20 ± 10.23

homozygous

95.52 ± 30.38

97.28 ± 24.60

96.90 ± 19.51

101.03 ± 11.93

99.82 ± 10.29

*) significant differences (p < 0.05) in lung function parameters between genotypes are printed in bold letters,

*^vdenotes significant differences in variance analysis,

*^ddenotes significant differences in t-test for a dominant model,

*^rsignificant differences in t-test for a recessive model

¹⁾N refers to the first lung function parameter. Minimal deviations of N in the other lung function parameters are possible.

Table 3b

Lung function parameters in the case-control study for all controls *)

SNP

N ¹⁾

MEF₂₅(%) Mean ± SD

MEF₅₀(%) Mean ± SD

MEF₇₅(%) Mean ± SD

FEV1 (%) Mean ± SD

FVC (%) Mean ± SD

F+1

wild type

291

98.48 ± 25.83

97.93 ± 19.80

99.22 ± 17.82

100.59 ± 9.86

98.28 ± 10.49

heterozygous

348

101.46 ± 30.46

99.08 ± 21.41

100.69 ± 17.83

101.76 ± 10.29

99.08 ± 10.26

homozygous

111

99.44 ± 29.96

99.63 ± 20.23

101.52 ± 19.80

101.38 ± 10.75

98.47 ± 10.38

M+1

wild type

522

99.25 ± 27.06

98.22 ± 20.12

99.46 ± 17.92*^d

101.06 ± 10.11

98.46 ± 10.51

heterozygous

201

101.97 ± 32.25

100.01 ± 21.94

102.51 ± 18.60

102.10 ± 10.69

99.39 ± 10.29

homozygous

95.45 ± 35.80

104.74 ± 19.55

104.98 ± 13.31

98.63 ± 8.56

96.65 ± 8.30

wild type

627

100.12 ± 29.00

99.05 ± 20.58

100.58 ± 17.89

101.18 ± 10.28

98.67 ± 10.52

heterozygous

116

98.23 ± 27.90

97.01 ± 21.40

99.16 ± 19.84

101.78 ± 10.41

99.29 ± 10.11

homozygous

95.19 ± 21.20

98.62 ± 16.03

103.61 ± 13.45

103.74 ± 10.25

100.29 ± 11.22

wild type

381

99.51 ± 26.91

98.44 ± 20.04

98.82 ± 17.78*^d

100.94 ± 10.08

98.34 ± 10.67

heterozygous

292

101.59 ± 31.92

99.11 ± 22.33

101.88 ± 18.68

102.09 ± 10.56

99.55 ± 10.28

homozygous

97.76 ± 25.55

100.37 ± 16.24

101.35 ± 16.99

102.51 ± 9.76

98.97 ± 9.91

ST+4

wild type

257

100.02 ± 28.64

98.04 ± 20.98

100.06 ± 17.63

101.58 ± 9.86

99.20 ± 9.75

heterozygous

365

100.09 ± 28.74

99.28 ± 21.10

101.17 ± 19.05

101.39 ± 10.50

98.55 ± 10.50

homozygous

114

98.52 ± 28.40

98.83 ± 18.79

98.41 ± 16.62

100.07 ± 10.09

98.18 ± 11.43

ST+5

wild type

222

100.79 ± 31.48

101.33 ± 20.02*^d

101.79 ± 17.87

101.33 ± 10.00

98.98 ± 10.29

heterozygous

380

99.54 ± 28.10

97.52 ± 21.27

99.77 ± 18.20

100.85 ± 10.58

98.12 ± 10.82

homozygous

148

99.48 ± 25.81

97.72 ± 19.54

99.23 ± 18.08

102.19 ± 9.46

99.74 ± 9.19

ST+7

wild type

507

100.34 ± 28.71

99.01 ± 20.67

100.26 ± 17.65

101.40 ± 10.17

98.93 ± 10.29

heterozygous

213

98.76 ± 29.25

98.00 ± 20.58

100.11 ± 19.04

100.65 ± 9.99

98.01 ± 10.35

homozygous

101.56 ± 24.74

98.45 ± 20.33

99.70 ± 19.21

103.37 ± 12.14

100.57 ± 12.16

wild type

531

99.34 ± 27.07

98.23 ± 20.15

99.49 ± 18.08

101.07 ± 10.13

98.58 ± 10.53

heterozygous

205

101.94 ± 32.34

99.58 ± 21.96

101.97 ± 18.39

101.81 ± 10.47

99.12 ± 10.14

homozygous

95.29 ± 31.85

103.19 ± 18.07

101.58 ± 14.14

101.17 ± 9.28

98.59 ± 8.47

wild type

532

99.31 ± 27.05

98.23 ± 20.13

99.51 ± 18.07

101.07 ± 10.12

98.57 ± 10.52

heterozygous

204

102.01 ± 32.41

99.58 ± 22.01

101.92 ± 18.42

101.80 ± 10.49

99.09 ± 10.16

homozygous

95.29 ± 31.85

103.19 ± 18.07

101.58 ± 14.14

101.17 ± 9.28

98.59 ± 8.47

wild type

474

100.07 ± 28.66

98.91 ± 21.18

100.74 ± 18.35

101.32 ± 10.45

98.76 ± 10.49

heterozygous

249

99.87 ± 29.37

98.91 ± 19.75

99.86 ± 17.75

101.62 ± 9.80

99.16 ± 10.07

homozygous

99.31 ± 25.64

96.87 ± 19.30

100.16 ± 19.15

100.29 ± 11.81

96.95 ± 12.34

*) significant differences in lung function parameters between genotypes are printed in bold letters,

*^vdenotes significant differences in variance analysis,

*^ddenotes significant differences in t-test for a dominant model,

*^rsignificant differences in t-test for a recessive model

¹⁾N refers to the first lung function parameter. Minimal deviations of N in the other lung function parameters are possible.

Haplotype analysis

In a further step, haplotypes were estimated in both populations for all samples genotyped successfully for at least one ADAM33 SNP (1,802 in the case control population and 782 in the MAS cohort) using the EM algorithm. The estimated frequencies of all common ADAM33 haplotypes built from the eight SNPs F+1, S1, S2, ST+4, ST+5, ST+7, T1 and V4 and all ten SNPs are presented in table 4. As SNPs M+1, T1 and T2 were in extremely tight linkage disequilibrium, polymorphisms M+1 and T2 contributed no additional information to the haplotype and thus were excluded from the further haplotype building procedure.

Table 4

Estimated frequencies of common haplotypes in different German populations

Estimated frequencies in the different populations³

F+1

M+1²

ST4

ST+5

ST+7

T2²

pooled

case-control study

cohort study

31.59% (31.62%)

31.42% (31.43%)

32.21% (32.24%)

16.63% (16.66%)

16.66% (16.67%)

16.54% (16.62%)

14.00% (13.91%)

14.67% (14.67%)

12.50% (12.20%)

11.22% (11.20%)

11.02% (11.01%)

11.48% (11.48%)

7.84% (7.84%)

7.73% (7.73%)

8.12% (8.12%)

6.48% (6.50%)

6.68% (6.70%)

6.06% (6.07%)

Rare¹

12.24% (12.28%)

11.82% (11.80%)

13.10% (13.27%)

¹⁾Rare are all haplotypes with an estimated frequency < 0.03 in the pooled sample

²⁾SNPs which are excluded after choosing only tagging SNPs

³⁾Estimated frequencies of the 8-SNP-haplotype, in brackets estimated frequencies of the 10-SNP-haplotype

One common haplotype, H4 (G-G-G-C-C-G-T-G), showed a weak but not significant association with asthma in the case control population but not in the cohort as indicated in table 5a. This association became significant in the pooled analysis. No association was found with BHR (data not shown). When a haplotype trend regression was performed for the haplotype H4, an OR of 1.57 (95%CI 0.99–2.51, p = 0.057) in the pooled population was observed.

Table 5

Estimated haplotype frequencies and associations with asthma in case control and cohort populations

Haplotype

Study population ¹⁾

Haplotype frequencies in the cases

Haplotype frequencies in the controls

Odds Ratio and Confidence intervals ²⁾

p-value of χ²-Test

G-G-G-A-T-G-T-C

all

30.35%

32.21%

0.92(0.78–1.08)

0.293

ccs

30.90%

31.56%

0.97(0.81–1.15)

0.735

coh

30.03%

34.02%

0.83(0.58–1.19)

0.317

G-G-G-C-C-G-T-C

all

17.02%

16.69%

1.02(0.84–1.25)

0.804

ccs

16.77%

16.85%

0.99(0.80–1.24)

0.939

coh

16.93%

16.32%

1.04(0.67–1.63)

0.847

A-G-C-A-C-G-C-C

all

12.98%

14.08%

0.91(0.73–1.13)

0.402

ccs

13.60%

14.85%

0.90(0.71–1.15)

0.406

coh

10.33%

12.04%

0.84(0.49–1.45)

0.531

G-G-G-C-C-G-T-G

all

12.96%

10.44%

1.28(1.02–1.60)

0.033

ccs

13.15%

10.65%

1.27(0.99–1.64)

0.063

coh

11.43%

9.85%

1.18(0.70–2.00)

0.528

A-A-C-A-T-A-T-G

all

8.35%

7.69%

1.09(0.83–1.43)

0.517

ccs

8.62%

7.16%

1.22(0.90–1.66)

0.191

coh

7.18%

9.07%

0.78(0.41–1.46)

0.430

A-G-G-C-C-A-T-C

all

6.70%

6.54%

1.03(0.76–1.38)

0.867

ccs

6.17%

6.67%

0.92(0.65–1.30)

0.638

coh

8.99%

6.19%

1.50(0.82–2.72)

0.184

¹⁾All = case control study and cohort study population pooled, ccs = case control study (n = 358 cases/n = 1198 controls), coh = cohort study (n = 82 cases/n = 464 controls); children without haplotype information were excluded

²⁾Odds Ratios were calculated as one haplotype vs. all others

Gene environment interaction analysis

As it was hypothesised that ADAM33 could influence the effects of passive smoke exposure on asthma, BHR or lung function, gene environment interactions were assessed using a Botto Khoury approach. However, no such interactions could be detected (data not shown).

Discussion

We have genotyped 2,696 subjects including more than 700 children with asthma and/or BHR for 10 SNPs in the ADAM33 gene. For doctor's diagnosed asthma, no SNP showed a significant association in any of the analyzed populations. A trend for somewhat more profound but not significant effects of ADAM33 SNPs was observed in individuals with asthma and BHR, for which trait the most significant association results were reported in the original study on ADAM33. However, in the case control population, these associations did just not reach statistical significance. Haplotype analyses suggested a minor effect of the ADAM33 haplotype H4 on asthma but not BHR. A number of individual SNPs showed an association with non atopic asthma in the case control population. A diverse picture evolved when the effects of ADAM33 polymorphisms on baseline lung function were measured. However, these associations did not remain significant after correction for multiple testing. No interaction with passive smoke exposure could be detected.

ADAM33 was the first published candidate gene for asthma identified by positional cloning. In the initial report 37 SNPs in the ADAM33 gene have been identified and 15 polymorphisms have been genotyped in a UK and a US study population 1. Even within these two populations, different SNPs were associated with asthma and BHR. Associations were significantly stronger in those cases additionally showing BHR, suggesting that ADAM33 acts via lung specific mechanisms. A putatively functional role for ADAM33 in the pathogenesis of asthma has been hypothesised as ADAM33 is expressed in smooth muscle cells of the bronchial and vascular system in the lung 120. It has been speculated that ADAM33 may act as a protease activating cytokine or induce airway smooth muscle proliferation. ADAM33 and its so far identified polymorphisms may have less to do with atopic inflammation and more with non atopic lung specific forms of asthma. To a somewhat lesser degree, this initial BHR effect was confirmed in our study population.

In terms of replication on a population level, the role of ADAM33 SNPs in asthma remains controversial. It seems that even the studies reporting a positive association between ADAM33 SNPs and atopic phenotypes are inhomogeneous in their findings (table 6). These inconsistencies in replication may have different reasons. They could be due to population heterogeneity, as some studies may suggest. Howard and co-workers genotyped 8 SNPs in 4 different ethnical populations (Dutch, white Americans, Hispanics and African Americans) and found a wide variety of associations between the different ethnical groups and various ADAM33 SNPs 4. No single SNP was associated with asthma in all 4 groups and when corrected for multiple testing, only one association remained significant. In studies of asthmatics with a Hispanic background, no association with ADAM33 SNPs was observed with asthma 21. Thus, differences in haplotype structure or even in the occurrence of SNPs may exist between ethnicities, which have not yet been investigated sufficiently for ADAM33 but which are known to exist for a number of other genes.

Table 6

Comparison of previously reported association results¹with ADAM33 polymorphisms

Study

Study population

N²

ADAM33 SNPs and reported associations

cc = case control

fa = family study

cases/controls families (ind.)

F+1

L-1

M+1

Q-1

ST+1

ST+4

ST+5

ST+7

T+1

V-1

Van Eerdewegh et al.

US/UK combined (cc)

130/217

neg

UK (cc)

(not reported)

neg

US (cc)

(not reported)

neg

US/UK (fa)

460fa (1840)

neg

Lind et al.

Mexican (cc)

190/160

neg

Puerto Rican (cc)

183/165

neg

Mexican/P. Rican (fa)

583fa (1749)³

neg

Raby et al.⁴

Non-Hispanic white (fa)

474 (1462)

neg

Hispanic (fa)

47 (149)

neg

African American (fa)

66 (203)

neg

Werner et al.

German (cc)

48/499

neg

German (fa)

171fa (732)

A, B, AB

neg

B, AB

neg

Howard et. al.

African American (cc)

161/265⁵

neg

US White (cc)

220/229⁵

neg

A⁶, AT

neg

A, AT

neg

US Hispanic (cc)

113/127⁵

neg

A⁶, AT

A, AT

neg

Dutch White (cc)

180/133⁵

neg

A, AT

neg

Blakey et al.

Icelandic (cc)

348/262

neg

Nottingham (fa)

60fa (240)

neg

¹association with asthma (= A), BHR (= B), Asthma and BHR (= AB) or Atopy (= AT) in different studies; SNPs which are not significantly associated = neg

²in case-control studies number of cases and controls, in family studies number of families and individuals

³265 Mexican families and 318 Puerto Rican families, no association neither in single nor in pooled population

⁴in the study of Raby et al. 8 additional SNPs were investigated: G1, I1, KL+3, N1, S+1, T+2, V-2, V3. None of the additional SNPs showed an association with asthma.

⁵N is reported as maximum number of successfully genotyped subjects

⁶only a trend (0.05 < p ≤ 0.06)

A further explanation for the differences in replication results might be that the definition of asthma may have varied between studies. As ADAM33 may specifically affect remodeling of the lungs, the impact of genetic variations in ADAM33 could be variable in different forms of asthma. In other words, ADAM33 genetics may have more impact on those forms of asthma which are less driven by atopy and more associated with lung specific mechanisms. Our data indeed suggests that the known ADAM33 SNPs have only a minor impact on the most common form of childhood asthma, which is highly correlated with atopy in most study populations. In contrast, a number of ADAM33 SNPs were associated with non atopic asthma as well as baseline lung function measurements in our study. However, the pattern of association remains complex as different SNPs are associated with non atopic asthma and determinants of lung function. Moreover, ADAM33 SNPs also seem to play a different role in adult asthma than in childhood asthma as indicated by previously published studies. Werner et al. genotyped 15 ADAM33 SNPs in a family based and in an adult case control population and observed variable associations between SNPs and asthma within the two populations and also in respect to the initially reported associations 7. Very large studies investigating childhood asthma by Lind 21 and Raby 6 could not find any association between single ADAM33 SNPs or haplotypes and childhood asthma. However, no analyses of ADAM33 effects on non atopic asthma have been reported in these studies of childhood asthma. While Raby et al. 6 stated that it seems very unlikely that these negative studies were underpowered to detect an association, a recent meta analysis suggested, that the odds ratio for the ADAM33 locus may be in the order of 1.4 or lower for SNPs known to date 3. Even with large data sets such as used in this study, the ability to detect risks of this magnitude may be limited. Furthermore, it may be possible that the known SNPs in ADAM33 are only a proxy for additional, yet unidentified SNPs in the ADAM33 gene, which could be the true cause for the observed but mixed signals from this locus.

Finally, differences in the study populations in terms of gene by environment interactions may also explain some of the observed discrepancy in replication as has been suggested to be the case with other genes inconsistently replicated 2223. However, it is not clear, which environmental factors may interact with ADAM33 genetics and if these factors could influence the associations between ADAM33 polymorphisms and asthma. As indicated by our analysis, passive smoke exposure does not seem to be one of these factors.

In the meantime, a total of five genes (ADAM331, PHF1124, DPP10 25GPRA 26 and HLA-G 27 have been proposed as potential asthma genes by positional cloning and some more may follow. What can we learn from the experience with ADAM33? First, it seems that genes identified by positional cloning have the same limitations as other putative candidate genes suggested by expression studies, or selected because of their biological context in disease pathways. Positional cloning does not prove but suggest a role of the gene in question for a specific disease. Further evidence however can only be achieved by independent replication studies and functional molecular genetics, which both may be tedious. This process may take some time and the level of evidence for or against the involvement of a certain gene in a complex disease may only increase with time. Large and well defined replications are needed and negative results ought to be published.

Conclusion

Our data suggest that previously reported ADAM33 polymorphisms may only have a minor impact on the development of asthma in German children.

Abbreviations

ADAM33 a disintegrin and metalloprotease 33

BHR bronchial hyperresponsiveness

EM expectation-maximisation

FEV1 forced expiratory volume in one second

FVC forced vital capacity

IgE immunoglobulin E

ISAAC II International Study of Asthma and Allergy in Childhood

LD linkage disequilibrium

MAS Multicentre Allergy Study

MALDI-TOF Matrix-assisted laser desorption time of flight

MEF maximum expiratory flow

OR odds ratio

PC₂₀Provocative concentration inducing a 20% fall in FEV1

PCR polymerase chain reaction

SNP single nucleotide polymorphism

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

MS participated in genotyping, data analysis and manuscript preparation; MD performed data analysis and participated in manuscript preparation; CS, NK and TI participated in genotyping, CF, CV, BN and SL collected data; SW, UW, EvM, RN and MK contributed to the development of the study design, collection of data, data analysis, and manuscript preparation.

Acknowledgements

We would like to thank Anja Pleiss for her excellent technical assistance. This study was funded by the German ministry of education and research as part of the German national genome research network with grants GS 01 0122, GS 01 0172, GS 01 0002, GS 01 0429, IE S08T03, IE S08T06, by the German research foundation (DFG-Grant NI-916-2) and by the Sonnenfeld- Foundation.

Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness Van Eerdewegh P Little RD Dupuis J Del Mastro RG Falls K Simon J Torrey D Pandit S McKenny J Braunschweiger K Walsh A Liu Z Hayward B Folz C Manning SP Bawa A Saracino L Thackston M Benchekroun Y Capparell N Wang M Adair R Feng Y Dubois J FitzGerald MG Huang H Gibson R Allen KM Pedan A Danzig MR Umland SP Egan RW Cuss FM Rorke S Clough JB Holloway JW Holgate ST Keith TP Nature 2002 418 426 430 10.1038/nature00878 12110844 ADAM33 gene: confirming a gene without linkage Postma DS Howard T Clin Exp Allergy 2004 34 1 3 10.1111/j.1365-2222.2004.01845.x 14720254 Contribution of ADAM33 polymorphisms to the population risk of asthma Blakey J Halapi E Bjornsdottir US Wheatley A Kristinsson S Upmanyu R Stefansson K Hakonarson H Hall IP Thorax 2005 60 274 276 10.1136/thx.2004.027227 15790980 Association of a disintegrin and metalloprotease 33 (ADAM33) gene with asthma in ethnically diverse populations Howard TD Postma DS Jongepier H Moore WC Koppelman GH Zheng SL Xu J Bleecker ER Meyers DA J Allergy Clin Immunol 2003 112 717 722 10.1016/S0091-6749(03)01939-0 14564349 Polymorphisms of the ADAM33 gene are associated with accelerated lung function decline in asthma Jongepier H Boezen HM Dijkstra A Howard TD Vonk JM Koppelman GH Zheng SL Meyers DA Bleecker ER Postma DS Clin Exp Allergy 2004 34 757 760 10.1111/j.1365-2222.2004.1938.x 15144468 ADAM33 polymorphisms and phenotype associations in childhood asthma Raby BA Silverman EK Kwiatkowski DJ Lange C Lazarus R Weiss ST J Allergy Clin Immunol 2004 113 1071 1078 10.1016/j.jaci.2004.03.035 15208587 Asthma is associated with single-nucleotide polymorphisms in ADAM33 Werner M Herbon N Gohlke H Altmuller J Knapp M Heinrich J Wjst M Clin Exp Allergy 2004 34 26 31 10.1111/j.1365-2222.2004.01846.x 14720258 A disintegrin and metalloprotease 33 polymorphisms and lung function decline in the general population van Diemen CC Postma DS Vonk JM Bruinenberg M Schouten JP Boezen HM Am J Respir Crit Care Med 2005 172 329 333 10.1164/rccm.200411-1486OC 15879414 Prevalence of respiratory and atopic disorders among children in the East and West of Germany five years after unification Weiland SK von Mutius E Hirsch T Duhme H Fritzsch C Werner B Husing A Stender M Renz H Leupold W Keil U Eur Respir J 1999 14 862 870 10.1034/j.1399-3003.1999.14d23.x 10573234 Increasing prevalence of hay fever and atopy among children in Leipzig, East Germany von Mutius E Weiland SK Fritzsch C Duhme H Keil U Lancet 1998 351 862 866 10.1016/S0140-6736(97)10100-3 9525363 Reactivity to cold-air hyperventilation in normal and in asthmatic children in a survey of 5,697 schoolchildren in southern Bavaria. Nicolai T vMutius EV Reitmeir P Wjst M Am Rev Respir Dis 1993 147 565 572 8442588 Natural course of sensitization to food and inhalant allergens during the first 6 years of life Kulig M Bergmann R Klettke U Wahn V Tacke U Wahn U J Allergy Clin Immunol 1999 103 1173 1179 10.1016/S0091-6749(99)70195-8 10359902 Associations between total serum IgE levels and the 6 potentially functional variants within the genes IL4, IL13, and IL4RA in German children: the German Multicenter Atopy Study Liu X Beaty TH Deindl P Huang SK Lau S Sommerfeld C Fallin MD Kao WH Wahn U Nickel R J Allergy Clin Immunol 2003 112 382 388 10.1067/mai.2003.1635 12897746 Histamine challenges discriminate between symptomatic and asymptomatic children. MAS-Study Group. Multicentre Allergy Study Niggemann B Illi S Madloch C Volkel K Lau S Bergmann R von Mutius E Wahn U Eur Respir J 2001 17 246 253 10.1183/09031936.01.17202460 11334127 A signal transducer and activator of transcription 6 haplotype influences the regulation of serum IgE levels Schedel M Carr D Klopp N Woitsch B Illig T Stachel D Schmid I Fritzsch C Weiland SK Von Mutius E Kabesch M J Allergy Clin Immunol 2004 114 1100 1105 10.1016/j.jaci.2004.07.048 15536416 Haploview: analysis and visualization of LD and haplotype maps Barrett JC Fry B Maller J Daly MJ Bioinformatics 2005 21 263 265 10.1093/bioinformatics/bth457 15297300 Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population Excoffier L Slatkin M Mol Biol Evol 1995 12 921 927 7476138 Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals Zaykin DV Westfall PH Young SS Karnoub MA Wagner MJ Ehm MG Hum Hered 2002 53 79 91 10.1159/000057986 12037407 Commentary: facing the challenge of gene-environment interaction: the two-by-four table and beyond Botto LD Khoury MJ Am J Epidemiol 2001 153 1016 1020 10.1093/aje/153.10.1016 11384958 Human ADAM33 messenger RNA expression profile and post-transcriptional regulation Umland SP Garlisi CG Shah H Wan Y Zou J Devito KE Huang WM Gustafson EL Ralston R Am J Respir Cell Mol Biol 2003 29 571 582 10.1165/rcmb.2003-0028OC 12777249 ADAM33 is not associated with asthma in Puerto Rican or Mexican populations Lind DL Choudhry S Ung N Ziv E Avila PC Salari K Ha C Lovins EG Coyle NE Nazario S Casal J Torres A Rodriguez-Santana JR Matallana H Lilly CM Salas J Selman M Boushey HA Weiss ST Chapela R Ford JG Rodriguez-Cintron W Silverman EK Sheppard D Kwok PY Gonzalez Burchard E Am J Respir Crit Care Med 2003 168 1312 1316 10.1164/rccm.200306-877OC 12958057 Genetics, epigenetics, and the environment: Switching, buffering, releasing Vercelli D J Allergy Clin Immunol 2004 113 381 386 10.1016/j.jaci.2004.01.752 15007332 Learning from discrepancies: CD14 polymorphisms, atopy and the endotoxin switch Vercelli D Clin Exp Allergy 2003 33 153 155 10.1046/j.1365-2222.2003.01606.x 12580903 Positional cloning of a quantitative trait locus on chromosome 13q14 that influences immunoglobulin E levels and asthma Zhang Y Leaves NI Anderson GG Ponting CP Broxholme J Holt R Edser P Bhattacharyya S Dunham A Adcock IM Pulleyn L Barnes PJ Harper JI Abecasis G Cardon L White M Burton J Matthews L Mott R Ross M Cox R Moffatt MF Cookson WO Nat Genet 2003 34 181 186 10.1038/ng1153 12754510 Positional cloning of a novel gene influencing asthma from chromosome 2q14 Allen M Heinzmann A Noguchi E Abecasis G Broxholme J Ponting CP Bhattacharyya S Tinsley J Zhang Y Holt R Jones EY Lench N Carey A Jones H Dickens NJ Dimon C Nicholls R Baker C Xue L Townsend E Kabesch M Weiland SK Carr D von Mutius E Adcock IM Barnes PJ Lathrop GM Edwards M Moffatt MF Cookson WO Nat Genet 2003 35 258 263 10.1038/ng1256 14566338 Characterization of a common susceptibility locus for asthma-related traits Laitinen T Polvi A Rydman P Vendelin J Pulkkinen V Salmikangas P Makela S Rehn M Pirskanen A Rautanen A Zucchelli M Gullsten H Leino M Alenius H Petays T Haahtela T Laitinen A Laprise C Hudson TJ Laitinen LA Kere J Science 2004 304 300 304 10.1126/science.1090010 15073379 Fine mapping and positional candidate studies identify HLA-G as an asthma susceptibility gene on chromosome 6p21 Nicolae D Cox NJ Lester LA Schneider D Tan Z Billstrand C Kuldanek S Donfack J Kogut P Patel NM Goodenbour J Howard T Wolf R Koppelman GH White SR Parry R Postma DS Meyers D Bleecker ER Hunt JS Solway J Ober C Am J Hum Genet 2005 76 349 357 1196380 15611928 10.1086/427763